PET/CT Improves Detection of Inoperable Lung Cancer (07/02/2009) Preoperative lung cancer staging with combined PET/CT imaging allows some patients to avoid futile surgery. These results were published in the New England Journal of Medicine.
Amgen Helps Reduce Out-of-pocket Costs for Neulasta® (07/02/2009) Amgen’s Neulasta FIRST STEP™ Program provides assistance to eligible, low-income, commercially-insured chemotherapy patients who need help with their co-insurance or co-payment requirement for Neulasta® (pegfilgrastim).
Sutent® Fails to Show Benefit in Metastatic Colorectal Cancer (07/01/2009) The combination of the targeted therapy Sutent® (sunitinib) and FOLFIRI chemotherapy did not result in better progression-free survival than FOLFIRI alone among patients with metastatic colorectal cancer, prompting a Phase III clinical trial of the combination treatment to be stopped early. This information was made available in a press release from Pfizer.
Sprycel® Superior to High-dose Gleevec® in Gleevec-resistant CML (07/01/2009) Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according to the results of a study published early online in Cancer.
CIN Associated with Long-term Risk of Recurrence and Invasive Cervical Cancer (06/30/2009) Women who have undergone treatment for cervical intraepithelial neoplasia (CIN) have a long-term increased risk of developing invasive carcinoma or a recurrence of CIN and, as such, need long-term surveillance, according to the results of a study published in the Journal of the National Cancer Institute.